Springe direkt zu Inhalt

Symposium | Pharmacy: Young Scientists Present

Jul 08, 2022 | 09:00 AM - 12:30 PM

The Deutsche Pharmazeutische Gesellschaft, Landesgruppe Berlin-Brandenburg and the Institute of Pharmacy, Freie Universität Berlin, warmly invite you to the 12 th Scientific Symposium "Young Scientists present":

Program  (PDF)

Oral Presentations

09:00 – 09:05 Welcome - Prof. Dr. Charlotte Kloft

Part 1 - Chair: Prof. Dr. Jörg Rademann
V1 09:05 – 09:20
M. Dubau, T. Tripetchr, B. Kleuser
Autologous approach to develop an immunocompetent skin model using iPSC-
generated fibroblast, keratinocytes, and immune cells

V2 09:20 – 09:35
Y. Jia, C. Arkona, Y. Pfeifer, L. Deng, B. Kuropka, C. Fröhlich, K. Ataka, S.
Bergemann, G. Wolber, H.-K. S. Leiros, M. Mielke, G. Werner, J. Rademann
Fragment-based development of inhibitors of New Delhi metallo- β-lactamase-1
(NDM-1) and validation of their mode-of-action against multiresistant bacteria

V3 09:35 – 09:50
F. Klima, A. Mc Laughlin, E. Schmulenson, O. Teplytska, S. Zimmermann, P.
Opitz, S. Groenland, A. Huitema, N. Steeghs, S. Fuxius, M. Joerger, F. Mayer, U.
Fuhr, S. Holdenrieder, G. Hempel, O. Scherf-Clavel, G. Mikus, U. Jaehde, C. Kloft
Feasibility of Therapeutic Drug Monitoring for targeted oral anticancer drugs in
clinical routine: The ON-TARGET study

V4 09:50 – 10:05
T. M. P. Neumann-Tran, D. Klinger
Turning the defense mechanism of antibiotic resistant bacteria against
themselves: New Polymer-Drug-Conjugates

10:05 – 10:10 Short break

Part 2 - Chair: Prof. Dr. Charlotte Kloft
V5 10:10 – 10:25
T. Noonan, D. Schaller, R. Nikolay, C. Spahn, M. Bermudez, G. Wolber
A novel antibiotic target: Identifying bacterial ribosomal assembly inhibitors via
3D pharmacophore-based virtual screening

V6 10:25 – 10:40
K. Pail, R. Bodmeier
Effect of glycerine on the conformation of Poloxamer P407 and its implication on
the nano-milling of a poorly water-soluble drug

V7 10:40 – 10:55
M. K. Parr, Y. Sun, L. Harps, M. Bureik
Human sulfotransferase assay with PAPS production in situ

10:55 – 11:00 Closing of Oral Presentation Sessions

11:00 – 12:30 Poster Presentation Session


  • P1 M. N. Alam, A. Dashevskiy, R. Bodmeier
    Pulsatile drug release from compression-coated tablets
  • P2 A. M. Ambros, P. Hailer, C. Arkona, G. Wolber, J. Rademann
    Molecular modeling and chemical optimization of fragment-based inhibitors of STAT5 as a novelbanti-leukemia strategy
  • P3 L. B. S. Aulin, R. Michelet, M. Ursino, S. Boulet, J. C. Sirard, E. Comets, S. Zohar, C. Kloft
    The FAIR approach: Utilising a modelling and simulation workflow leveraging multisource data to support preclinical development and clinical trials
  • P4 D. Bindellini, D. Busse, P. Simon, R. Michelet, D. Petroff, L. B. S. Aulin, C. Dorn, M. Zeitlinger, H. Wrigge, W. Huisinga, C. Kloft
    Semi-mechanistic model-based analysis to evaluate differences in plasma and target site cefazolin pharmacokinetics and protein binding in obese and nonobese patients
  • P5 M. Breznik, S. Pach, S. Gobec, G. Wolber
    Retrosynthesis-driven in silico optimization of antiviral agents targeting 3C and 3C-like proteases
  • P6 Y. Chen, Q. T. Wang
    The application oft he MM/GBSA method in the binding pose prediction of FGFR inhibitors
  • P7 A. Démaris, E. L. Plan, W. Huisinga, L. B. S. Aulin, S. H. Lee, J. H. Lee, W. Reinisch, R. Michelet, C. Kloft
    Characterising and predicting the risk of immunogenicity in Crohn’s disease patients receiving infliximab therapy
  • P8 P. Demirel, C. Arkona, J. Rademann
    Pre-biotic evolution of functional peptides through templated synthesis
  • P9 K. Denzinger, M. Dündüz, G. Wolber
    Probing the binding pockets of L-type and T-type calcium channels using dynamic pharmacophores – a new approach for pain medication
  • P10 Y. Dyck, D. Rehm, K. Winkler, V. Sandig, W. Jabs, M. K. Parr
    Identification of susceptible residues in a monoclonal antibody after forced degradation by peptide mapping
  • P11 Y. Fan, M. K. Parr
    Complete reaction phenotyping of propranolol and 4-hydroxypropranolol with the 19 enzymes of the human UGT1 and UGT2 families
  • P12 L. Gerlach
    Establishment of a method to determine the cell number of Schizosaccharomyces pombe for the standardisation of biotransformation assays
  • P13 G. Giacomello, C. Boettcher, M. K. Parr
    Development and validation of a method to trace 13 C through glucose metabolism
  • P14 T. Heinrich, A. Dashevskiy, R. Bodmeier
    Effect of ethanol on the release mechanism from hydrophilic matrix tablets
  • P15 S. Kanwal, T. M. P. Neumann-Tran, D. Klinger
    New antimicrobial polymers to fight against resistant bacteria
  • P16 F. Kias, R. Bodmeier
    Diafiltration-assisted solvent extraction for achieving rapid organic solvent removal during the preparation of biodegradable poly(lactide-co-glycolide) (PLGA) microparticles
  • P17 D. Klemczak, A. Horatscheck, R. Raz, J. P. Kries, S. Bergemann, A. V. Rudnev, P. Broekmann, J. Rademann
    Peroxygenins (POG) are redox-activated inhibitors of protein tyrosine phosphatases and target cells with high reduction potential
  • P18 A. P. Konrad, F. Bredendieck, F. Schumacher, C. Kloft
    Bioanalytical method development for the determination of target-site concentrations of posaconazole
  • P19 L. Lassak, J. Rademann
    Pentafluorophosphato-phosphonates: biomimetics of organic pyrophosphates?
  • P20 L. Y. Liu, L. Hobohm, F. Bredendieck, A. Froschauer, O. Zierau, M. K. Parr, A. M. Keiler
    Medaka embryos as a model for metabolism of anabolic steroids
  • P21 S. Liu, F. Yang, M. K. Parr, G. Wolber
    Comparative modelling of human Uridine 5’-diphosphoglucuronosyltransferase guided by molecular dynamics (MD) simulations
  • P22 C. López-Iglesias, R. Cui, A. Markovina, A. Gruber, D. Klinger
    Synthesis, characterization, and applications of amphiphilic nanogels based on polymethacrylates and polycarbonates
  • P23 S. Märker, M. Körber, R. Bodmeier
    Mechanical properties of biodegradable poly(lactide-co-glycolide) (PLGA) implants determined by a three-point bending test
  • P24 H. Mitdank, M. Tröger, A. Sonntag, N. A. Shirazi, E. Woith, H. Fuchs, D. Kobelt, W. Walther, A. Weng
    Suicide nanoplasmids coding for ribosome-inactivating proteins
  • P25 F. L. Mueller, L. Ilia, K. Foerster, J. Burhenne, R. Michelet, C. Kloft
    Variability in protein binding determination: A comparison of microdialysis, ultrafiltration and rapid equilibrium dialysis
  • P26 S. Pach, D. Schaller, G. Wolber
    Extracting 3D pharmacophores from molecular dynamics simulations: A case study
  • P27 A. Prell, ,F. Schumacher, D. Wigger, B. Kleuser
    Target and off-target effects of sphingosine kinase inhibitors on the sphingolipidome in different cell lines
  • P28 K. Puls, H. Schmidhammer, G. Wolber, M. Spetea
    Enlightment through dynamics: How the peripheral analgesic HS-731 discriminates between opioid receptors
  • P29 A. Saoud, J. Rademann
    Pore-blockers: Small-molecule inhibitors of cholesterol-dependent cytolysins
  • P30 L. Schlaak, C. Weise, B. Kuropka, A. Weng
    Sapovaccarin-S1 and -S2, two type I ribosome-inactivating protein isoforms from the seeds of Saponaria vaccaria L.
  • P31 K. Schreck, M. F. Melzig
    The expression of selected intestinal glucose, fructose and long chain fatty acid transporters investigated in Caco-2 cells
  • P32 W. Song, J. Rademann
    Development of orthosteric inhibitors of SHP2
  • P33 A. Sonntag, H. Mitdank, A. Weng
    Construction of Minicircle suicide genes coding for ribosome-inactivating proteins
  • P34 J. Steff, X. de la Torre, F. Botrè, M. K. Parr
    Stereoselective chemosynthetic approach to obtain metabolites of metandienone with a fully reduced A-ring as reference material
  • P35 V. Talagayev, A. Dolsak, D. Sribar, G. Wolber, M. Sova, G. Weindl
    An innovative approach fo Toll-like receptor dynamics exploitation for structure optimization through 3D pharmacophore analysis
  • P36 M. Tiemann, M. Accorsi, L. Wehrhan, L. M. Finn, R. Cruz, M. Rautenberg, F. Emmerling, J. Heberle, B. G. Keller, J. Rademann
    Pentafluorphosphato-phenyl-alanines as amphiphilic mimetics of phosphotyrosine
  • P37 T. Tripetchr, M. Dubau, B. Kleuser
    Development of a skin sensitization assay using in vitro immunocompetent skin models
  • P38 R. Wamser, S. Pach, C. Arkona, M. Baumgardt, U. B. A. Aziz, A. Hocke, G. Wolber, R. Rademann
    Covalent inhibitors of SARS-CoV-2 main protease targeting the S1-site with pyridine fragments
  • P39 T. Wang, S. Staufenbiel, R. Bodmeier
    Preparation and characterization of a stabilizer-free dexamethasone oily nanosuspension
  • P40 F. E. Weber, F. A. Weinelt, M. Stegemann, A. Theloe, F. Pfäfflin, L. Aulin, U. Trost,W. Huisinga, S. Hennig, C. Kloft
    Optimising meropenem dosing in the intensive care unit with a model-informed precision dosing tool: The TIAS study
  • P41 E. Widigson, D. Busse, D. Bindellini, D. Petroff, C. Dorn, L. B. Aulin, R. Michelet, M. Zeitlinger, W. Huisinga, H. Wrigge, P. Simon, C. Kloft
    A pharmacometric evaluation of atypical plasma protein binding and probability of target attainment of tigecycline in obese and nonobese patients
  • P42 E. Woith, A. Jendretzki, A. von zur Gathen, M. F. Melzig
    Plant extracellular vesicle lipids and secondary metabolites
  • P43 C. A. Wolf, S. Liu, D. Machalz, J. Zhao, M. K. Parr, M. Bureik, G. Wolber
    Observing subtle changes in conformational dynamics caused by mutation P340A in orphan cytochrome P450 3A43 for drug design
  • P44 W. Xie, M. F. Melzig
    The stability of medicinal plant microRNAs in herb preparation process
  • P45 G. Ambrosio, T. Yuliandra, K. Touvleliou, B. Wuest, M. Mazzarino, X. de la Torre, F. Botrè, P. Diel, E. Isenmann, M. K. Parr
    Excretion study of ecdysterone following a single-dose administration in humans
  • P46 C. Zhang, R. Bodmeier
    Encapsulating dexamethasone nanocrystals into PLGA microparticles by a simplified solvent evaporation process
  • P47 X. Zhang, J. Rademann
    Development and evaluation of fragment-based inhibitors of SARS-CoV-2 main protease
  • P48 N. Zimmermann, B. Pourshacheraghi, S. Wolf, T. Semmler, C. Kloft
    Integrated in vitro approach to understand the exposure-effect relationship of fosfomycin against Escherichia coli

Time & Location

Jul 08, 2022 | 09:00 AM - 12:30 PM

Königin-Luise-Straße 12-16, 14195 Berlin